PEG MGF

Name: PEG MGF
Brand: LyoPep

Also known as PEG-MGF

PEG-conjugated MGF E-peptide research material · architecture must be defined by lot

Lot-specific · Batch COACAS Confirm per batch COARUO

MOQ1 kit (10 vials) per SKU

Supplied formHeterogeneous PEG–peptide conjugate unless PEG size, attachment site, linker and substitution ratio are explicitly fixed

Lead time14–21 days

PEG MGF — Lot-specific lyophilized conjugate; appearance alone does not establish PEG architecture, identity or content

PEG MGF — Lot-specific lyophilized conjugate; appearance alone does not establish PEG architecture, identity or content · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Defensible research value includes PEG-conjugate characterization, free-versus-conjugated peptide comparison, architecture–activity studies, myoblast or progenitor assay replication, stability and analytical method development
Muscle repair, hypertrophy, recovery or anti-ageing claims are not established and direct human evidence is absent.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: Confirm per batch COA
Formula: Confirm supplied form on batch COA
Molecular weight: Confirm supplied form on batch COA
Appearance: Lot-specific lyophilized conjugate; appearance alone does not establish PEG architecture, identity or content
Purity: Architecture- and lot-specific; require peptide identity/content, PEG distribution, conjugation-site evidence, free peptide/free PEG and aggregate results · target, verify batch COA
Storage: Follow released-lot label, COA and conjugate-specific stability data. Generic 2–8°C or reconstituted-storage advice is not transferable across PEG architectures and matrices.
MOQ: 1 kit (10 vials) per SKU
Lead time: 14–21 days

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about PEG MGF

PEG-MGF is a supplier-dependent PEG conjugate of an MGF/IGF-1Ec E-domain-related peptide. Without fixed PEG size, dispersity, linker, attachment site and substitution ratio, it is not one defined compound and has no universal formula, mass or CAS. Non-PEGylated MGF-E peptide cell studies are conflicting: Kandalla et al. reported effects in human muscle progenitor cells, whereas Fornaro/Brace et al. found no apparent effect in myoblasts or primary muscle stem cells. Those studies do not establish performance or efficacy of an unspecified PEG conjugate.

Appropriate laboratory contexts include conjugate identity and mass-distribution methods, PEG architecture comparison, free-versus-conjugated peptide assays, replication of conflicting muscle-cell findings, stability and recovery studies
No approved clinical indication applies.

Mechanism context

The question the literature is testing

MGF E-peptide mechanisms remain disputed, and PEGylation can alter target access as well as exposure. It is therefore incorrect to state that PEG only changes half-life while leaving activity unchanged. Experiments require matched unconjugated controls, architecture-resolved characterization, quantitative recovery and activity assays.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research

Research areaRepair and regenerative research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary administration
Human safety data are absent, conjugate identity may vary, and growth-factor-related mitogenic risk cannot be excluded
MGFs are prohibited under the 2026 WADA Prohibited List
Incorrect architecture, free PEG or peptide, aggregates, impurities, contamination and unsupported content assignment are material risks.

Interactions reported in the literature

No human combination guidance applies
BPC-157, TB-500, IGF-1 LR3, GH, CJC-1295, ipamorelin, MK-677 and insulin claims were removed because no controlled co-administration evidence supports them.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

PEG MGF batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

2 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

Require peptide identity and content, PEG nominal mass and dispersity, linker, conjugation site, substitution distribution, intact-mass envelope or conjugate mapping, free peptide, free PEG, aggregates, related peptides, water, residual solvents, container integrity and lot-specific stability
No single CAS, formula, nominal mass or HPLC purity can qualify the conjugate.

Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

PEGMGF22 mg10 vials

Handling

Plan storage before the parcel arrives

Follow released-lot label, COA and conjugate-specific stability data. Generic 2–8°C or reconstituted-storage advice is not transferable across PEG architectures and matrices.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

1) Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. (2011) "Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages." Mechanisms of Ageing and Development 132(4):154-162, PMID 21354439, doi:10.1016/j.mad.2011.02.007. This in-vitro study used non-PEGylated MGF-E peptide in human muscle progenitor cells; it is not direct evidence for an unspecified PEG conjugate.
2) Fornaro M, Hinken AC, Needle S, et al. (2014) "Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells." American Journal of Physiology-Endocrinology and Metabolism 306(2):E150-E156, PMID 24253050, doi:10.1152/ajpendo.00408.2013. Concentrations up to 500 ng/ml produced no proliferative or anti-differentiation effect in the reported cell models, directly conflicting with earlier positive findings.
3) Rotwein P. (2014) "Editorial: The Fall of Mechanogrowth Factor?" Molecular Endocrinology 28(2):155-156, PMID 24460193, PMC3896639, doi:10.1210/me.2013-1411. The contemporaneous editorial discusses the conflicting MGF literature, possible confirmation bias and the need for independent replication.
4) Mills P, Lafrenière JF, Benabdallah BF, El Fahime EM, Tremblay JP. (2007) "A new pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain of the mechano growth factor." Experimental Cell Research 313(3):527-537, PMID 17156777, doi:10.1016/j.yexcr.2006.10.032. This is non-PEGylated peptide evidence in cell and transplantation models, not qualification of a PEG-MGF material.
5) Sun KT, Cheung KK, Au SWN, Yeung SS, Yeung EW. (2018) "Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury." Frontiers in Physiology 9:999, PMID 30140235, PMC6094977, doi:10.3389/fphys.2018.00999. This mouse model studied MGF overexpression rather than a chemically defined PEG-MGF conjugate.

01
Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation
FEBS Letters · 2002 · peer-reviewed original research
Open source
02
Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction
Heart, Lung and Circulation · 2008 · peer-reviewed original research (animal model)
Open source
03
The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction
Molecular and Cellular Biochemistry · 2013 · peer-reviewed original research (in vitro and murine model)
Open source
04
Minireview: Mechano-Growth Factor: A Putative Product of IGF-I Gene Expression Involved in Tissue Repair and Regeneration
Endocrinology · 2010 · peer-reviewed minireview (critical/skeptical)
Open source
05
Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells
American Journal of Physiology-Endocrinology and Metabolism · 2014 · peer-reviewed original research (contradicting findings)
Open source
06
Editorial: The Fall of Mechanogrowth Factor?
Molecular Endocrinology · 2014 · peer-reviewed editorial (critical/skeptical)
Open source
07
The role of mechano growth factor in chondrocytes and cartilage defects: a concise review
Acta Biochimica et Biophysica Sinica (Shanghai) · 2023 · peer-reviewed review
Open source
08
Mechano growth factor E peptide regulates migration and differentiation of bone marrow mesenchymal stem cells
Journal of Molecular Endocrinology · 2014 · peer-reviewed original research
Open source

Product FAQ

Questions buyers ask about PEG MGF

Why can two PEG-MGF materials with the same name be non-equivalent?+

PEG molecular mass, dispersity, linear or branched architecture, linker, attachment site and PEG-to-peptide substitution distribution can all differ. These variables change intact-mass distribution, chromatography, recovery, activity and clearance. The name alone does not define a molecule; compare complete released-lot specifications and orthogonal analytical data.

What should a decision-ready PEG-MGF COA include?+

Require the exact MGF-related peptide sequence and terminal state, PEG identity, nominal mass and dispersity, linker and conjugation site, substitution distribution, intact-mass or conjugate-mapping evidence, peptide content, free peptide, free PEG, aggregates, related peptides, water, residual solvents, container and lot-specific stability. A single HPLC area purity or nominal PEG mass is insufficient.

Evidence before order

PEG MGF

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about PEG MGF

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

PEG MGF batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Plan storage before the parcel arrives

Terms to settle before the purchase order

Literature behind the research context

Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation

Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction

The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction

Minireview: Mechano-Growth Factor: A Putative Product of IGF-I Gene Expression Involved in Tissue Repair and Regeneration

Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells

Editorial: The Fall of Mechanogrowth Factor?

The role of mechano growth factor in chondrocytes and cartilage defects: a concise review

Mechano growth factor E peptide regulates migration and differentiation of bone marrow mesenchymal stem cells

Questions buyers ask about PEG MGF

Buyer intelligence

Compare adjacent molecules and documentation needs.

MGF

IGF-1 LR3

GHK-Cu

TB-500 (Thymosin Beta-4, full-length)